Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Period	YoY Revenue Growth
2017-12-31	N/A
2018-12-31	54.14%
2019-12-31	-99.79%
2020-12-31	44631.25%
2021-12-31	-4.44%
2022-12-31	-2.84%
2023-12-31	125.73%
2024-12-31	624.05%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PTGX	$104.08	+0.00%	0.70M
3
4
5

Protagonist Therapeutics Inc. (PTGX) Revenue Growth

Revenue Growth Data

Get Protagonist Therapeutics Inc. Data in Excel

More PTGX Financial Data